Cue Biopharma received notice from Boehringer Ingelheim approving the first compound for lead optimization under their collaboration, triggering a $7.5 million preclinical milestone payment expected in May 2026.
Key takeaways
On April 1, 2026, Boehringer Ingelheim approved selection of its first compound for lead optimization under the April 10, 2025 Collaboration and License Agreement.
The agreement covers research, development, and commercialization of differentiated B cell depletion molecules, including CUE-501.
This preclinical milestone triggers a $7.5 million payment to Cue Biopharma.